SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-25
acquisitionAnnounced · Feb 23, 2026biotechnologySource · CredibleArticle · Factual
Gilead Sciences acquires Arcellx
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$7.8B
Target
Arcellx
NASDAQ: ACLX · Redwood City, California
Acquirer
Gilead Sciences
Full Acquisition
Status
Announced
Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Announced. Sector: biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion , sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading
Deal timeline
Announced
Feb 23, 2026 · finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $7.8B. Figures and status may change as sources update.
Sources: finance.yahoo.com · Primary article · FireStrike proprietary index